CN103189511B - 利用siRNA导入的新型hiPSC制作法 - Google Patents

利用siRNA导入的新型hiPSC制作法 Download PDF

Info

Publication number
CN103189511B
CN103189511B CN201180043814.8A CN201180043814A CN103189511B CN 103189511 B CN103189511 B CN 103189511B CN 201180043814 A CN201180043814 A CN 201180043814A CN 103189511 B CN103189511 B CN 103189511B
Authority
CN
China
Prior art keywords
cells
seq
base sequence
stranded
polynucleotide
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Expired - Fee Related
Application number
CN201180043814.8A
Other languages
English (en)
Chinese (zh)
Other versions
CN103189511A (zh
Inventor
三浦典正
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Tottori University NUC
Original Assignee
Tottori University NUC
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Tottori University NUC filed Critical Tottori University NUC
Publication of CN103189511A publication Critical patent/CN103189511A/zh
Application granted granted Critical
Publication of CN103189511B publication Critical patent/CN103189511B/zh
Expired - Fee Related legal-status Critical Current
Anticipated expiration legal-status Critical

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N15/00—Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
    • C12N15/09—Recombinant DNA-technology
    • C12N15/11—DNA or RNA fragments; Modified forms thereof; Non-coding nucleic acids having a biological activity
    • C12N15/113—Non-coding nucleic acids modulating the expression of genes, e.g. antisense oligonucleotides; Antisense DNA or RNA; Triplex- forming oligonucleotides; Catalytic nucleic acids, e.g. ribozymes; Nucleic acids used in co-suppression or gene silencing
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/70—Carbohydrates; Sugars; Derivatives thereof
    • A61K31/7088—Compounds having three or more nucleosides or nucleotides
    • A61K31/7105—Natural ribonucleic acids, i.e. containing only riboses attached to adenine, guanine, cytosine or uracil and having 3'-5' phosphodiester links
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/70—Carbohydrates; Sugars; Derivatives thereof
    • A61K31/7088—Compounds having three or more nucleosides or nucleotides
    • A61K31/713—Double-stranded nucleic acids or oligonucleotides
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A61P1/16—Drugs for disorders of the alimentary tract or the digestive system for liver or gallbladder disorders, e.g. hepatoprotective agents, cholagogues, litholytics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A61P1/18—Drugs for disorders of the alimentary tract or the digestive system for pancreatic disorders, e.g. pancreatic enzymes
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00—Drugs for disorders of the respiratory system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00—Drugs for dermatological disorders
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P21/00—Drugs for disorders of the muscular or neuromuscular system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07H—SUGARS; DERIVATIVES THEREOF; NUCLEOSIDES; NUCLEOTIDES; NUCLEIC ACIDS
    • C07H21/00—Compounds containing two or more mononucleotide units having separate phosphate or polyphosphate groups linked by saccharide radicals of nucleoside groups, e.g. nucleic acids
    • C07H21/02—Compounds containing two or more mononucleotide units having separate phosphate or polyphosphate groups linked by saccharide radicals of nucleoside groups, e.g. nucleic acids with ribosyl as saccharide radical
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N15/00—Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
    • C12N15/09—Recombinant DNA-technology
    • C12N15/11—DNA or RNA fragments; Modified forms thereof; Non-coding nucleic acids having a biological activity
    • C12N15/111—General methods applicable to biologically active non-coding nucleic acids
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N5/00—Undifferentiated human, animal or plant cells, e.g. cell lines; Tissues; Cultivation or maintenance thereof; Culture media therefor
    • C12N5/06—Animal cells or tissues; Human cells or tissues
    • C12N5/0602—Vertebrate cells
    • C12N5/0696—Artificially induced pluripotent stem cells, e.g. iPS
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2310/00—Structure or type of the nucleic acid
    • C12N2310/10—Type of nucleic acid
    • C12N2310/11—Antisense
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2310/00—Structure or type of the nucleic acid
    • C12N2310/10—Type of nucleic acid
    • C12N2310/14—Type of nucleic acid interfering nucleic acids [NA]
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2320/00—Applications; Uses
    • C12N2320/30—Special therapeutic applications
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2501/00—Active agents used in cell culture processes, e.g. differentation
    • C12N2501/65—MicroRNA

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Organic Chemistry (AREA)
  • Genetics & Genomics (AREA)
  • Biomedical Technology (AREA)
  • General Health & Medical Sciences (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Molecular Biology (AREA)
  • Biochemistry (AREA)
  • Biotechnology (AREA)
  • Zoology (AREA)
  • Wood Science & Technology (AREA)
  • Animal Behavior & Ethology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Medicinal Chemistry (AREA)
  • General Engineering & Computer Science (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Microbiology (AREA)
  • Physics & Mathematics (AREA)
  • Biophysics (AREA)
  • Plant Pathology (AREA)
  • Epidemiology (AREA)
  • Cell Biology (AREA)
  • Transplantation (AREA)
  • Developmental Biology & Embryology (AREA)
  • Neurology (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Orthopedic Medicine & Surgery (AREA)
  • Physical Education & Sports Medicine (AREA)
  • Neurosurgery (AREA)
  • Pulmonology (AREA)
  • Dermatology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Micro-Organisms Or Cultivation Processes Thereof (AREA)
CN201180043814.8A 2010-07-12 2011-06-28 利用siRNA导入的新型hiPSC制作法 Expired - Fee Related CN103189511B (zh)

Applications Claiming Priority (7)

Application Number Priority Date Filing Date Title
JP2010-158192 2010-07-12
JP2010-158193 2010-07-12
JP2010158194 2010-07-12
JP2010158192 2010-07-12
JP2010-158194 2010-07-12
JP2010158193 2010-07-12
PCT/JP2011/064846 WO2012008301A1 (ja) 2010-07-12 2011-06-28 ｓｉＲＮＡ導入による新規ｈｉＰＳＣ作製法

Publications (2)

Publication Number Publication Date
CN103189511A CN103189511A (zh) 2013-07-03
CN103189511B true CN103189511B (zh) 2016-10-12

Family

ID=45469308

Family Applications (2)

Application Number Title Priority Date Filing Date
CN201180043814.8A Expired - Fee Related CN103189511B (zh) 2010-07-12 2011-06-28 利用siRNA导入的新型hiPSC制作法
CN201180043810XA Pending CN103097535A (zh) 2010-07-12 2011-06-28 利用miRNA导入的新型hiPSC制作法

Family Applications After (1)

Application Number Title Priority Date Filing Date
CN201180043810XA Pending CN103097535A (zh) 2010-07-12 2011-06-28 利用miRNA导入的新型hiPSC制作法

Country Status (5)

Country Link
US (2) US9476041B2 (enExample)
EP (2) EP2594644B1 (enExample)
JP (5) JP5099571B2 (enExample)
CN (2) CN103189511B (enExample)
WO (2) WO2012008302A1 (enExample)

Families Citing this family (13)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2012008302A1 (ja) 2010-07-12 2012-01-19 国立大学法人鳥取大学 ｍｉＲＮＡ導入による新規ｈｉＰＳＣ作製法
EP4086338A1 (en) 2011-03-17 2022-11-09 Minerva Biotechnologies Corporation Method for making pluripotent stem cells
WO2013059373A2 (en) 2011-10-17 2013-04-25 Minerva Biotechnologies Corporation Media for stem cell proliferation and induction
US10034902B2 (en) * 2012-02-22 2018-07-31 Exostem Biotec Ltd. MicroRNAs for the generation of astrocytes
JP6748430B2 (ja) * 2012-07-13 2020-09-02 ミネルバ バイオテクノロジーズ コーポレーション より未分化状態への細胞の誘導方法
US10265347B2 (en) 2013-08-29 2019-04-23 Norimasa Miura Biomolecular group related to cell anti-aging
US20160289678A1 (en) * 2013-11-22 2016-10-06 Dcb-Usa Llc Use of microrna 146-a in the diagnosis, treatment and prevention of picornavirus infection and microrna 146-a antagonists
CN104109670B (zh) * 2014-03-12 2018-01-05 首都医科大学附属北京安定医院 一种双链siRNA分子及其应用
SG11201610745XA (en) 2014-06-27 2017-01-27 Rhizen Pharmaceuticals Sa Substituted chromene derivatives as selective dual inhibitors of pi3 delta and gamma protein kinases
EP3286335A4 (en) 2015-04-24 2018-10-17 The Johns Hopkins University Compositions and methods related to characterizing proviral reservoirs
WO2017073689A1 (ja) * 2015-10-30 2017-05-04 国立大学法人鳥取大学 Ｄｎａ損傷を修復するｒｎａ分子
KR102011336B1 (ko) * 2015-12-31 2019-08-16 인터올리고 주식회사 약물 전달 및 안정화를 위한 복합체 및 그 제조방법
WO2018203553A1 (ja) * 2017-05-02 2018-11-08 株式会社ペジィー・ファーマ 分化細胞の品質改善方法

Citations (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2006112239A1 (ja) * 2005-04-15 2006-10-26 National University Corporation Tottori University ｈＴＥＲＴ発現調節遺伝子
CN101333524A (zh) * 2008-06-25 2008-12-31 中山大学 一个小分子非编码RNA基因hsa-miR-101及其抗肿瘤用途

Family Cites Families (19)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP1452594A4 (en) * 2001-11-15 2007-01-10 Kyowa Hakko Kogyo Kk INDUCTOR FOR DIFFERENTIATING EMBRYOONAL STEM CELLS TO EODODERMAL CELLS, METHOD FOR OBTAINING THEM AND USE THEREOF
WO2004024940A2 (en) 2002-09-16 2004-03-25 University Of Southern California Rna-mediated gene modulation
KR20050115231A (ko) 2003-02-10 2005-12-07 내셔날 인스티튜트 오브 어드밴스드 인더스트리얼 사이언스 앤드 테크놀로지 포유동물 세포의 조절
US9453219B2 (en) 2003-05-15 2016-09-27 Mello Biotech Taiwan Co., Ltd. Cosmetic designs and products using intronic RNA
EP2314688B1 (en) 2004-11-12 2014-07-16 Asuragen, Inc. Methods and compositions involving miRNA and miRNA inhibitor molecules
WO2006084275A2 (en) 2005-02-04 2006-08-10 Auburn University Contact drug delivery system
PL2002003T3 (pl) * 2005-05-27 2016-06-30 Ospedale San Raffaele Srl Wektor genetyczny zawierający mi-RNA
WO2006137514A1 (ja) 2005-06-23 2006-12-28 Locomogene, Inc. シノビオリンの発現もしくは機能阻害物質を有効成分とする癌治療剤、および癌治療剤のスクリーニング方法
KR101420740B1 (ko) 2005-12-13 2014-07-17 교또 다이가꾸 핵초기화 인자
EP2487260B1 (en) 2006-01-05 2015-07-08 The Ohio State University Research Foundation Microrna-based methods and compositions for the diagnosis and treatment of solid cancers
KR101407707B1 (ko) 2006-04-03 2014-06-19 산타리스 팔마 에이/에스 Ａｎｔｉ-ｍｉｒｎａ 안티센스 올리고뉴클레오타이드를 함유하는 약학적 조성물
CN101980712B (zh) * 2007-10-29 2015-02-18 雷古拉斯治疗公司 用于肝癌治疗的靶向微小rna
KR101564044B1 (ko) 2007-10-31 2015-10-28 고쿠리츠 다이가쿠 호진 교토 다이가쿠 핵초기화 방법
KR101532442B1 (ko) 2007-12-10 2015-06-29 고쿠리츠 다이가쿠 호진 교토 다이가쿠 효율적인 핵 초기화 방법
CA2710713C (en) * 2007-12-27 2017-09-19 Protiva Biotherapeutics, Inc. Silencing of polo-like kinase expression using interfering rna
CN101970664B (zh) * 2008-01-16 2013-08-21 林希龙 使用可诱导的重组核糖核酸因子生成不含肿瘤的类胚胎干细胞的多能性细胞
CN101392251B (zh) * 2008-11-03 2015-07-22 清华大学深圳研究生院 能诱导干细胞向成骨细胞分化的微小rna及其应用
JP2010120881A (ja) * 2008-11-19 2010-06-03 Keio Gijuku ヒト癌タンパク質ＭＤＭ２とヒト癌抑制タンパク質ｐ５３との相互作用阻害ペプチド及びその使用
WO2012008302A1 (ja) 2010-07-12 2012-01-19 国立大学法人鳥取大学 ｍｉＲＮＡ導入による新規ｈｉＰＳＣ作製法

Patent Citations (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2006112239A1 (ja) * 2005-04-15 2006-10-26 National University Corporation Tottori University ｈＴＥＲＴ発現調節遺伝子
CN101333524A (zh) * 2008-06-25 2008-12-31 中山大学 一个小分子非编码RNA基因hsa-miR-101及其抗肿瘤用途

Non-Patent Citations (1)

* Cited by examiner, † Cited by third party
Title
A noncoding RNA gene on chromosome 10p15.3 may function upstream of hTERT;Norimasa Miura等;《BMC Molecular Biology》;20090202;第10卷(第5期);第5页 *

Also Published As

Publication number Publication date
CN103189511A (zh) 2013-07-03
CN103097535A (zh) 2013-05-08
JP5099571B2 (ja) 2012-12-19
JP2014097059A (ja) 2014-05-29
JP5099570B2 (ja) 2012-12-19
JPWO2012008301A1 (ja) 2013-09-09
JP2013046616A (ja) 2013-03-07
EP2594643B1 (en) 2017-04-12
EP2594644A1 (en) 2013-05-22
US9476041B2 (en) 2016-10-25
US9790491B2 (en) 2017-10-17
WO2012008302A1 (ja) 2012-01-19
JP2013034479A (ja) 2013-02-21
EP2594644A4 (en) 2014-12-24
EP2594644B1 (en) 2016-08-10
EP2594643A1 (en) 2013-05-22
EP2594643A4 (en) 2014-12-24
US20130190389A1 (en) 2013-07-25
JPWO2012008302A1 (ja) 2013-09-09
US20130184335A1 (en) 2013-07-18
JP5845493B2 (ja) 2016-01-20
WO2012008301A1 (ja) 2012-01-19

Similar Documents

Publication Publication Date Title
CN103189511B (zh) 利用siRNA导入的新型hiPSC制作法
US10752883B2 (en) Generation of neural stem cells and motor neurons
EP3401393B1 (en) Micrornas for the generation of astrocytes
JP5681955B2 (ja) 短いｒｎａ分子
EP3040414B1 (en) Biomolecular group related to cell anti-aging
US20190015453A1 (en) MicroRNAS FOR THE GENERATION OF ASTROCYTES
WO2011040613A1 (ja) 腫瘍治療剤
WO2014097875A1 (ja) 新規の脱分化誘導方法を用いた多能性幹細胞化
US20250059505A1 (en) Improved methods for inducing the maturation of mammalian cells
Caldoni Dissecting the role of IGF2BP3 in the stress-adaptive response and in intercellular communication in Ewing Sarcoma.
Nugroho Modulation of the Hippo signalling pathway by a novel miRNA to enhance cardiac regenerative capacity
TW202237839A (zh) 嵌合適體、其用途以及用於治療癌症之醫藥組合物
Buccini Cardiogenic differentiation of induced pluripotent stem cells for regeneration of the ischemic heart

Legal Events

Date Code Title Description
C06 Publication
PB01 Publication
C10 Entry into substantive examination
SE01 Entry into force of request for substantive examination
C14 Grant of patent or utility model
GR01 Patent grant
CF01 Termination of patent right due to non-payment of annual fee
CF01 Termination of patent right due to non-payment of annual fee

Granted publication date: 20161012

Termination date: 20180628